The story of Dr. M. Motasim Billah is a powerful testament to the transformative power of education, perseverance, and scientific curiosity. Rising from the remote coastal region of Char Fasson in southern Bangladesh to become one of the world’s respected biomedical scientists and pharmaceutical research leaders, his life represents an inspiring example of how determination can overcome even the greatest barriers.
Born and raised in Char Fasson, located at the southern edge of Bhola Island in the Bay of Bengal, Dr. Billah grew up during a period when educational opportunities in rural Bangladesh were extremely limited. In the 1950s and 1960s, the region had only a single secondary school and one madrasa serving a population of more than 100,000 people. Social expectations encouraged boys to join family businesses or farming, while girls were often married at an early age.
Against this backdrop, Dr. Billah’s parents made a bold and unconventional decision that would change the course of their family’s history. Although deeply rooted in a religious and scholarly family tradition, they chose secular education for all five of their sons. The children were sent away from home to pursue education at some of the finest institutions in the region, including Bhola Government High School and Barisal Zilla School.
Their investment in education produced extraordinary results. Three sons went on to earn doctoral degrees in scientific fields from universities in England, Canada, and Germany, while the remaining two became physicians. The remarkable accomplishments of her children earned Dr. Billah’s mother the affectionate title of “Ratnagarbha” or “Mother of Jewels” within the community.
Dr. Billah excelled academically from an early age. After completing his schooling in Barisal and Char Fasson with distinction, he continued his education at Dhaka College before enrolling in the Department of Biochemistry at the University of Dhaka. He graduated with First Class honors in both his Bachelor’s and Master’s degrees in Biochemistry and later joined the university as a lecturer.
His passion for science extended beyond the laboratory. During his time as a young academic, he wrote two science-themed dramas aimed at promoting scientific understanding among the public, reflecting his lifelong commitment to science communication.
In 1974, Dr. Billah received the prestigious British Commonwealth Scholarship to pursue doctoral studies at the University of Birmingham in the United Kingdom. He completed his PhD in Biochemistry in 1977 and continued for an additional year as a research fellow.
His scientific journey then took him to the United States, where he undertook postdoctoral research at Burroughs Wellcome & Co. in Research Triangle Park, North Carolina. It was there that he developed a deep appreciation for translational science — the process of converting laboratory discoveries into life-saving medicines for patients.
In 1983, Dr. Billah joined Schering-Plough Corporation, beginning a distinguished pharmaceutical career that would span more than two decades. His pioneering work in cellular signaling, inflammation, and immunology quickly established him as one of the company’s leading scientists.
His exceptional contributions earned him three Presidential Awards for Outstanding Research, an achievement unmatched in the company’s history. Rising through the ranks, he eventually became Senior Distinguished Research Fellow and Senior Director, leading multidisciplinary teams responsible for identifying novel therapeutic targets and developing innovative drug candidates.
Under his scientific leadership, research programs contributed to the development of numerous therapies for asthma, allergies, and chronic obstructive pulmonary disease (COPD). Among the medicines supported by his work were Clarinex®, an important anti-allergy medication, and Nasonex®, a widely prescribed treatment for allergic rhinitis.
Following successful brain surgery in 2004, Dr. Billah embraced a new professional challenge by transitioning into regulatory science. In 2008, he joined Bristol Myers Squibb, where he played a critical role in translating complex clinical data into regulatory submissions required for global drug approvals.
Over the next sixteen years, he contributed to the development and regulatory advancement of several globally significant therapies, including Opdivo® for cancer immunotherapy, Eliquis® for cardiovascular and thromboembolic diseases, and Orencia® for autoimmune disorders.
Dr. Billah retired in 2024, concluding an extraordinary 45-year career dedicated to improving human health through science and medicine.
Throughout his career, Dr. Billah became internationally recognized for his groundbreaking research on cellular communication and lipid signaling pathways. His studies helped explain how inflammatory processes occur in the body and how commonly used anti-inflammatory medications exert their effects. His discoveries advanced scientific understanding of diseases such as asthma, COPD, arthritis, and other chronic inflammatory disorders.
His scientific contributions are reflected in more than 100 peer-reviewed publications and numerous presentations at international conferences. His research appeared in prestigious journals, including The Journal of Biological Chemistry and The Biochemical Journal, where he later served as an editorial board member for a decade. He also holds the distinction of being a Member Emeritus of the American Society for Biochemistry and Molecular Biology.
Today, Dr. Billah enjoys retirement surrounded by his wife, children, and extended family, reflecting on a career that has touched countless lives through scientific discovery and medical innovation.
From the fields of rural Char Fasson to the laboratories and boardrooms of the world’s leading pharmaceutical companies, Dr. M. Motasim Billah’s journey stands as an enduring symbol of what education, vision, and perseverance can achieve. His life story continues to inspire future generations of Bangladeshis to dream beyond geographical boundaries and contribute to the advancement of humanity through knowledge and service.
